Inovio Pharmaceuticals, Inc. (INO)
1.36
+0.03
(+2.26%)
USD |
NASDAQ |
Sep 02, 16:00
1.35
-0.01
(-0.74%)
Pre-Market: 08:13
Inovio Pharmaceuticals Research and Development Expense (TTM) : 47.16M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 47.16M |
| March 31, 2026 | 50.82M |
| December 31, 2025 | 52.42M |
| September 30, 2025 | 55.38M |
| June 30, 2025 | 61.13M |
| March 31, 2025 | 70.06M |
| December 31, 2024 | 75.62M |
| September 30, 2024 | 79.99M |
| June 30, 2024 | 76.76M |
| March 31, 2024 | 77.41M |
| December 31, 2023 | 86.68M |
| September 30, 2023 | 111.54M |
| June 30, 2023 | 129.13M |
| March 31, 2023 | 161.85M |
| December 31, 2022 | 187.65M |
| September 30, 2022 | 237.83M |
| June 30, 2022 | 251.83M |
| March 31, 2022 | 266.17M |
| December 31, 2021 | 249.24M |
| September 30, 2021 | 183.24M |
| June 30, 2021 | 162.61M |
| March 31, 2021 | 114.18M |
| December 31, 2020 | 94.25M |
| September 30, 2020 | 89.95M |
| June 30, 2020 | 82.63M |
| Date | Value |
|---|---|
| March 31, 2020 | 82.74M |
| December 31, 2019 | 88.02M |
| September 30, 2019 | 92.38M |
| June 30, 2019 | 95.09M |
| March 31, 2019 | 95.07M |
| December 31, 2018 | 95.26M |
| September 30, 2018 | 93.53M |
| June 30, 2018 | 97.19M |
| March 31, 2018 | 98.61M |
| December 31, 2017 | 98.57M |
| September 30, 2017 | 97.84M |
| June 30, 2017 | 99.31M |
| March 31, 2017 | 95.07M |
| December 31, 2016 | 88.71M |
| September 30, 2016 | 80.40M |
| June 30, 2016 | 69.50M |
| March 31, 2016 | 66.55M |
| December 31, 2015 | 57.79M |
| September 30, 2015 | 51.43M |
| June 30, 2015 | 42.38M |
| March 31, 2015 | 35.30M |
| December 31, 2014 | 34.10M |
| September 30, 2014 | 31.25M |
| June 30, 2014 | 29.68M |
| March 31, 2014 | 24.48M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Fortress Biotech, Inc. | 1.186M |
| Tonix Pharmaceuticals Holding Corp. | 63.86M |
| Kura Oncology, Inc. | 259.47M |
| Spero Therapeutics, Inc. | 20.53M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |